

## Telix Pharma establishes new operations in Japan

05 June 2025 | News

**TMS Yokohama will serve as a hub for commercial and clinical supply**



Australia-headquartered Telix Pharmaceuticals has established Telix Manufacturing Solutions (TMS) in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company's global manufacturing strategy.

TMS Yokohama will serve as a hub for commercial and clinical supply, and future research and development in the region. It expands Telix's global production network which includes in-house and partner facilities. Originally opened in 2018, the site comprises a cyclotron and multiple production hot cells and was designed and built by JFE Engineering Corporation (JFE) as the Contract Manufacturing Organization (CMO) for TLX250-CDx (Zircaix®, <sup>89</sup>Zr-girentuximab) in Japan and China, including for the ZIRCON-CP study.

Taking over the lease and operational management of this facility will provide greater control over existing clinical supply with the possibility to expand production to other Telix investigational and future commercial products in the region, including Illuccix® (TLX591-CDx, <sup>68</sup>Ga-PSMA-11) and Pixclara® (TLX101-CDx, <sup>18</sup>F-floretyrosine) for Greater Tokyo, and TLX591 (<sup>177</sup>Lu rosopatamab tetraxetan) for the Asia Pacific region.

Further, the company plans to install Telix's ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, which it believes will facilitate standardised, high-efficiency and cost-effective production of commercially important medical isotopes.